AmbioPharm (Now a CordenPharma Subsidiary) Announces $118.96M Aiken County Peptide Manufacturing Expansion With 200+ Jobs
AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.